Incidental nonuterine high-grade serous carcinomas arise in the fallopian tube in most cases: Further evidence for the tubal origin of high-grade serous carcinomas

American Journal of Surgical Pathology

Volumn 39, Issue 3, 2015, Pages 357-364

  Gilks, C Blake ^a   Irving, Julie ^b   Köbel, Martin ^c   Lee, Chenghan ^d   Singh, Naveena ^e   Wilkinson, Nafisa ^f   McCluggage, W Glenn ^g  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ROYAL JUBILEE HOSPITAL   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

^e BARTS HEALTH NHS TRUST   (United Kingdom)

^f ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^g ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

Author keywords

fallopian tube; high grade serous carcinoma; site of origin; STIC

Indexed keywords

ADULT; AGED; CANCER GRADING; CARCINOMA IN SITU; CHEMISTRY; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMAN; HYSTERECTOMY; INCIDENTAL FINDING; MIDDLE AGED; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; OVARIECTOMY; PATHOLOGY; SALPINGECTOMY;

ADULT; AGED; CARCINOMA IN SITU; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; HYSTERECTOMY; INCIDENTAL FINDINGS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; OVARIECTOMY; SALPINGECTOMY;

EID: 84924025241     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000353     Document Type: Article

References (36)

1. Auersperg N, Wong AS, Choi KC, et al. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev. 2001;22: 255-288.
2. Tumours of the ovary and peritoneum. In: Tavassoli FA, Devilee P. World Health Organization Classification of Tumours: Tumours of the Breast and Female Genital Organs. Lyon: IARC Press; 2003:116.
3. Colgan TJ, Murphy J, Cole DE, et al. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol. 2001;25:1283-1289.
4. Piek JM, van Diest PJ, Zweemer RP, et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001;195:451-456.
5. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol. 2006;30:230-236.
6. Salvador S, Rempel A, Soslow RA, et al. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma. Gynecol Oncol. 2008;110:408-417.
7. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol. 2007;31:161-169.
8. Roh MH, Kindelberger D, Crum CP. Serous tubal intraepithelial carinoma and the dominant ovarian mass: clues to serous tumor origin? Am J Surg Pathol. 2009;33:376-383.
9. Tang S, Onuma K, Deb P, et al. Serous tubal intraepithelial carcinoma and the dominant ovarian mass: clues to serous tumor origin? Frequency of serous tubal intraepithelial carcinoma in various gynecologic malignancies: a study of 300 consecutive cases. Int J Gynecol Pathol. 2012;31:103-110.
10. Singh N, Gilks CB, Wilkinson N, et al. Assignment of primary site in high-grade serous tubal, ovarian and peritoneal carcinoma: a proposal. Histopathology. 2014;65:149-154.
11. Jarboe EA, Miron A, Carlson JW, et al. Coexisting intraepithelial serous carcinomas of the endometrium and fallopian tube: frequency and potential significance. Int J Gynecol Pathol. 2009;28: 308-315.
12. Rabban JT, Vohra P, Zaloudek C. Intramucosal growth in fallopian tube fimbriae by tumors of non-gynecologic origin may mimic serous tubal intraepithelial carcinoma and tubal mucinous metaplasia. Mod Pathol. 2014;27(S2):302A.
13. Rabban JT, Garg K, Crawford B, et al. Early detection of highgrade tubal serous carcinoma in women at low risk for hereditary breast and ovarian cancer syndrome by systematic examination of fallopian tubes incidentally removed during benign surgery. Am J Surg Pathol. 2014;38:729-742.
14. Holtz F, Hart WR. Krukenberg tumors of the ovary: a clinicopathologic analysis of 27 cases. Cancer. 1982;50:2438-2447.
15. Young RH, Gilks CB, Scully RE. Mucinous tumors of the appendix associated with mucinous tumors of the ovary and pseudomyxoma peritonei. A clinicopathological analysis of 22 cases supporting an origin in the appendix. Am J Surg Pathol. 1991;15:415-429.
16. Ronnett BM, Yemelyanova AV, Vang R, et al. Endocervical adenocarcinomas with ovarian metastases: analysis of 29 cases with emphasis on minimally invasive cervical tumors and the ability of the metastases to simulate primary ovarian neoplasms. Am J Surg Pathol. 2008;32:1835-1853.
17. Carlson JW, Miron A, Jarboe EA, et al. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol. 2008; 26:4160-4165.
18. Bijron JG, Seldenrijk CA, Zweemer RP, et al. Fallopian tube intraluminal tumor spread from non-invasive precursor lesions: a novel metastatic route in early pelvic carcinogenesis. Am J Surg Pathol. 2013;37:1123-1130.
19. Kuhn E, Meeker A, Wang TL, et al. Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis. Am J Surg Pathol. 2010;34:829-836.
20. Kuhn E, Bahadirli-Talbot A, Kurman R, et al. CCNE1 amplification may precede centrosome number abnormality in progression from serous tubal intraepithelial carcinoma to high-grade serous carcinoma. Mod Pathol. 2013;26(S2):283A.
21. Bashashati A, Ha G, Tone A, et al. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol. 2013;231:21-34.
22. Al-Hussaini M, Stockman A, Foster H, et al. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology. 2004;44:109-115.
23. McCluggage WG. WT1 is of value in ascertaining the site of origin of serous carcinomas within the female genital tract. Int J Gynecol Pathol. 2004;23:97-99.
24. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609-615.
25. The Cancer Genome Atlas Research Network. Integrated genomic analyses of endometrial carcinoma. Nature. 2013;497:67-73.
26. Alsop K, Fereday S, Meldrum C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012;30:2654-2663.
27. McAlpine JN, Porter H, Kö bel M, et al. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. Mod Pathol. 2012;25:740-750.
28. Leitao MM Jr, Boyd J, Hummer A, et al. Clinicopathologic analysis of early-stage sporadic ovarian carcinoma. Am J Surg Pathol. 2004;28:147-159.
29. Kobel M, Kalloger SE, Santos JL, et al. Tumor type and substage predict survival in stage I and II ovarian carcinoma: Insights and implications. Gynecol Oncol. 2010;116:50-56.
30. Society CC. Canadian Cancer Statistics. Toronto, ON: Canadian Cancer Society; 2014. Available at: http://www.cancer.ca/B/media/ cancer.ca/CW/cancer information/cancer 101/Canadian cancer statistics/Canadian-Cancer-Statistics-2014-EN.pdf. Accessed June 30, 2014.
31. Brown PO, Palmer C. The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med. 2009;6:e1000114.
32. Wethington SL, Park KJ, Soslow RA, et al. Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC). Int J Gynecol Cancer. 2013;23:1603-1611.
33. Conner JR, Meserve E, Pizer E, et al. Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingooophorectomy in women with germ-line BRCA1 or BRCA2 mutations. Gynecol Oncol. 2014;132:280-286.
34. Chan A, Gilks B, Kwon J, et al. New insights into the pathogenesis of ovarian carcinoma: time to rethink ovarian cancer screening. Obstet Gynecol. 2012;120:935-940.
35. McAlpine JN, Hanley GE, Woo MM, et al. Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention: Ovarian Cancer Research Program of British Columbia. Am J Obstet Gynecol. 2014;210:471, e1-11.
36. Gilks CB, Miller D. Opportunistic salpingectomy: the time has come. Gynecol Oncol. 2013;129:443-444.